First-ever experimental gene therapy seeks to restore vision by rejuvenating eye neurons
rael science
The Raelian Movement
Get Rael-Science on Facebook: http://www.facebook.com/raelscience
Get Rael-Science on Twitter: https://twitter.com/rael_science
First-ever experimental gene therapy seeks to restore vision by rejuvenating eye neurons
ER-100 uses epigenetic reprogramming to reset aging retinal cells, targeting glaucoma and optic nerve damage.
Life Biosciences is pushing cellular rejuvenation into the clinic with ER-100, an experimental gene therapy designed to restore vision by reviving damaged neurons in the eye.
Rather than slowing disease progression, the approach aims to reset aging retinal cells to a healthier state using epigenetic reprogramming.
ER-100 targets optic neuropathies, a group of conditions that cause irreversible vision loss when retinal ganglion cells, which connect the eye to the brain, die off.
These neurons do not naturally regenerate, making disorders such as open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy especially difficult to treat.
The therapy emerged from Life Bio’s Partial Epigenetic Reprogramming platform, which alters biochemical markers that control gene expression without changing DNA itself.
The method uses controlled expression of three Yamanaka transcription factors, OCT-4, SOX-2, and KLF-4, collectively known as OSK, to rewind cellular aging signatures.
In preclinical studies, ER-100 was delivered directly into the eye through intravitreal injection.
According to the company, the approach restored methylation patterns linked to cellular age and improved visual function in multiple animal models, including nonhuman primates. The therapy received FDA approval for first human trial last week.
Those results set the stage for a first-in-human evaluation focused on safety and early signs of benefit.
Rewriting vision at source
The clinical program will enroll patients with open-angle glaucoma and NAION, conditions that together represent a growing burden as populations age.
Glaucoma remains a leading cause of blindness worldwide, and while treatments often focus on lowering intraocular pressure, damage to retinal ganglion cells can continue even when pressure is controlled.
NAION, sometimes described as a stroke of the eye, causes sudden and painless vision loss and currently has no approved therapies
By targeting the underlying neuronal degeneration, ER-100 is positioned as a potential disease-modifying treatment rather than a symptomatic fix.
The Phase 1 study will assess safety, tolerability, immune responses, and changes across multiple visual assessments.
While early-stage trials are not designed to prove efficacy, the data could help validate epigenetic reprogramming as a viable strategy for neurodegenerative eye disease.
“This important milestone in reaching the clinic is the result of years of research, optimization, and comprehensive nonhuman primate studies demonstrating controlled OSK expression, restoration of methylation patterns, and improved visual function, all of which has culminated in this IND clearance,” said Sharon Rosenzweig-Lipson, Ph.D., Chief Scientific Officer, Life Biosciences.
“These results have paved the way for first-in-human evaluation of our cellular rejuvenation approach with the goal of improving the lives of people facing debilitating age-related disease, starting with optic neuropathies.”
Beyond pressure-based treatments
If successful, ER-100 could signal a broader shift in how age-related diseases are treated, moving from managing downstream effects to addressing biological aging itself
Life Bio is already positioning the platform beyond eye disorders, with plans to expand into additional age-related conditions where cellular damage accumulates over time.
For now, the focus remains on whether partial epigenetic reprogramming can be translated safely into humans.
The outcome of this early trial will be closely watched by researchers working on regenerative medicine, gene therapy, and the biology of aging, all of whom are seeking ways to restore function rather than simply slow decline.